KYMR•benzinga•
B of A Securities Maintains Neutral on Kymera Therapeutics, Lowers Price Target to $44
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga